CSF3 and End Stage Liver Disease: In a randomized, double-blind, single-center trial, G-CSF significantly improved 90-day survival and reduced model for end-stage liver disease (MELD) and Maddrey’s discriminant scores in patients with steroid-nonresponsive severe AH; the incidence of infections was also lower in the G-CSF group compared to placebo [84].